Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Expected to Rise, Deutsche Bank Aktiengesellschaft Analyst Says

Sarepta Therapeutics (NASDAQ:SRPT) had its price target lifted by equities research analysts at Deutsche Bank Aktiengesellschaft to $12.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “sell” rating on the biotechnology company’s stock. Deutsche Bank Aktiengesellschaft’s price target would suggest a potential downside of 44.98% from the stock’s previous close.

SRPT has been the subject of several other research reports. Mizuho reaffirmed a “neutral” rating and set a $14.00 price objective (down previously from $40.00) on shares of Sarepta Therapeutics in a report on Monday, July 21st. Citigroup assumed coverage on Sarepta Therapeutics in a report on Tuesday, July 22nd. They set a “sell” rating for the company. Sanford C. Bernstein assumed coverage on Sarepta Therapeutics in a research note on Tuesday, July 29th. They issued a “market perform” rating and a $13.00 price objective on the stock. Baird R W downgraded shares of Sarepta Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 18th. Finally, Piper Sandler raised their price objective on shares of Sarepta Therapeutics to $15.00 and gave the company a “neutral” rating in a research report on Tuesday, July 29th. Six research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Hold” and a consensus price target of $43.63.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock opened at $21.81 on Friday. The firm has a market capitalization of $2.13 billion, a P/E ratio of -25.07 and a beta of 0.46. The stock has a fifty day moving average price of $19.75 and a two-hundred day moving average price of $53.54. Sarepta Therapeutics has a 52-week low of $10.41 and a 52-week high of $144.22. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.89 and a quick ratio of 1.81.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.89 by $1.13. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The business had revenue of $611.09 million during the quarter, compared to analysts’ expectations of $530.66 million. During the same quarter last year, the company posted $0.07 EPS. The firm’s revenue for the quarter was up 68.4% on a year-over-year basis. As a group, analysts anticipate that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Byrne Asset Management LLC bought a new stake in Sarepta Therapeutics during the first quarter worth about $30,000. Center for Financial Planning Inc. acquired a new position in shares of Sarepta Therapeutics during the 1st quarter worth approximately $31,000. Logan Capital Management Inc. bought a new stake in shares of Sarepta Therapeutics during the 4th quarter worth approximately $61,000. Ancora Advisors LLC boosted its holdings in shares of Sarepta Therapeutics by 150.0% in the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 300 shares during the last quarter. Finally, Pandora Wealth Inc. bought a new position in shares of Sarepta Therapeutics in the first quarter valued at $45,000. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.